Global Psilocybin Clinical Trials Landscape 2026: Key Programs and Regulatory Milestones

The psilocybin clinical trial pipeline has expanded dramatically over the past five years, evolving from a handful of academic pilot studies to a robust portfolio of registrational trials sponsored by both biotech companies and academic institutions. As of early 2026, there are over 50 active or recruiting clinical trials involving psilocybin worldwide, investigating its therapeutic potential across a growing range of psychiatric and neurological conditions.

This article provides a comprehensive overview of the most significant clinical programs, their current status, the therapeutic indications being pursued, and the regulatory milestones that will shape the trajectory of the psilocybin API market over the coming years.

COMPASS Pathways: COMP360 for Treatment-Resistant Depression

The most advanced psilocybin clinical program globally is COMPASS Pathways' COMP360 — a proprietary, synthetic formulation of psilocybin being developed for treatment-resistant depression (TRD). COMPASS completed a landmark Phase 2b trial in 2022, demonstrating statistically significant dose-dependent reductions in depression severity at three weeks following a single 25 mg dose of COMP360.

The company has since initiated multiple Phase 3 trials (designated COMP001, COMP002, and COMP003) to generate the registrational data package required for FDA approval. The Phase 3 program is designed to confirm the efficacy and safety of COMP360 in a larger, more diverse patient population, with primary endpoints focused on changes in MADRS (Montgomery-Åsberg Depression Rating Scale) scores.

If the Phase 3 program is successful, COMPASS could submit a New Drug Application (NDA) to the FDA as early as 2027, with a potential approval decision in the 2027–2028 timeframe. This would represent the first FDA-approved psilocybin product — a watershed moment for the field and a catalyst for API demand.

Usona Institute: Psilocybin for Major Depressive Disorder

The Usona Institute, a non-profit research organization, is conducting Phase 2 trials of psilocybin for major depressive disorder (MDD) — a broader indication than TRD that affects approximately 21 million adults in the United States alone. Usona's program is notable for its academic sponsorship and its focus on a patient population that has not necessarily failed multiple prior antidepressant treatments.

Usona's Phase 2 trial (CLARITY) is evaluating a single 25 mg dose of synthetic psilocybin in combination with psychological support, with primary endpoints measuring changes in depression severity at six weeks. Positive results from this trial could support advancement to Phase 3 and potentially expand the addressable market for psilocybin therapy beyond treatment-resistant populations.

Psilocybin for Anxiety Disorders

Multiple academic groups are investigating psilocybin for anxiety-related conditions, including generalized anxiety disorder, social anxiety, and anxiety associated with life-threatening illness. Johns Hopkins University, New York University, and the University of Zurich are among the leading institutions conducting trials in this space.

A notable Phase 2 trial at Johns Hopkins is evaluating psilocybin-assisted therapy for anxiety and depression in patients with a cancer diagnosis — building on earlier landmark studies by Ross et al. (2016) and Griffiths et al. (2016) that demonstrated sustained reductions in anxiety and depression in cancer patients following psilocybin-assisted therapy.

Psilocybin for Substance Use Disorders

Psilocybin is also being investigated as a treatment for substance use disorders, including alcohol use disorder, tobacco/nicotine addiction, and opioid use disorder. The theoretical basis for these applications lies in psilocybin's ability to promote neuroplasticity and facilitate psychological insight — mechanisms that may help patients break entrenched patterns of addictive behavior.

A Phase 2 trial at the University of Wisconsin-Madison is evaluating psilocybin-assisted therapy for alcohol use disorder, while a separate program at Johns Hopkins is investigating psilocybin for tobacco smoking cessation. Early results from these programs have been encouraging, with abstinence rates substantially exceeding those typically observed with standard behavioral and pharmacological interventions.

Psilocybin for PTSD

Post-traumatic stress disorder (PTSD) represents another promising indication for psilocybin therapy. While MDMA-assisted therapy for PTSD has received the most attention (and faced regulatory setbacks), psilocybin is being investigated as a potential alternative or complementary approach.

A Phase 2 trial at the University of California, San Francisco is evaluating psilocybin-assisted therapy for PTSD in military veterans — a population with high treatment resistance and significant unmet medical need. The trial is assessing safety, tolerability, and preliminary efficacy using the Clinician-Administered PTSD Scale (CAPS-5) as the primary outcome measure.

International Clinical Programs

The clinical trial landscape extends well beyond the United States. Significant programs are underway in the United Kingdom, the Netherlands, Germany, Australia, and Canada.

In the UK, the COMPASS Pathways Phase 3 trials are being conducted at multiple sites, and Imperial College London continues its academic research program investigating psilocybin's mechanisms of action. In the Netherlands, the UMC Utrecht is conducting trials exploring psilocybin for depression and addiction. In Australia, where psilocybin was rescheduled for therapeutic use in July 2023, clinical programs are being established under the Therapeutic Goods Administration's authorized prescriber framework.

Regulatory Milestones to Watch

Several regulatory milestones over the next 2–3 years will significantly impact the psilocybin API market:

COMPASS Pathways Phase 3 readout (2026–2027): The results of the COMP001 and COMP002 Phase 3 trials will be the most closely watched data readouts in the field. Positive results would validate the therapeutic potential of psilocybin and support an NDA submission.

FDA NDA submission and review (2027–2028): If Phase 3 results are positive, COMPASS could submit an NDA in 2027. The FDA review process typically takes 10–12 months, with a potential approval decision in late 2027 or 2028.

European Medicines Agency (EMA) submissions: Following any FDA approval, EMA submissions for European market access would likely follow, with potential approvals in 2028–2029.

Additional indication approvals: If psilocybin is approved for TRD, subsequent approvals for MDD, anxiety disorders, and substance use disorders could follow over the following years, each expanding the addressable market and API demand.

Implications for API Supply

The clinical trial landscape has direct implications for psilocybin API supply. Each active trial requires a reliable source of GMP-certified psilocybin API — and as trials advance toward registration, the quantities required increase substantially. A Phase 3 trial with 200–300 participants may require 5–15 grams of pure API, while the stability studies, reference standard preparation, and regulatory documentation associated with an NDA submission require additional material.

More importantly, the transition from clinical supply to commercial supply — triggered by regulatory approval — would require a step change in production capacity. The current global supply of pharmaceutical-grade psilocybin API, estimated at less than 1 kg per year across all producers, would be wholly insufficient to meet the demand generated by a commercially launched product.

This supply-demand gap underscores the strategic importance of establishing new production capacity now — before the approval catalyst arrives. Manufacturers who achieve GMP certification and build customer relationships during the clinical trial phase will be best positioned to capture commercial supply contracts.

The psilocybin clinical trial pipeline is the most advanced it has ever been, with multiple Phase 3 programs approaching registrational data readouts. The next 24 months will be decisive — not only for the therapeutic future of psilocybin, but for the API supply chain that will underpin it.